Atai Beckley Shareholders Face a Two-Tiered Payout as Eli Lilly’s $3.8 Billion Psychedelic Bet Takes Shape
Published on 07/26/2026 at 17:13 | Redaktion boerse-global.de
The market has already priced in most of what Eli Lilly is willing to pay for Atai Beckley. Now the real debate begins over whether the remaining upside is worth the wait — or whether it will ever materialize at all.
Eli Lilly’s all-cash offer of $6.75 per share values the psychedelics specialist at roughly $2.8 billion. But the total transaction could reach $3.8 billion when contingent value rights — CVRs worth up to an additional $2.50 per share — are factored in. That represents a potential 72.6% premium from where the stock traded before the deal was announced, though the market has already absorbed most of that gain.
Atai Beckley shares closed Friday in German trading at €6.30, down 0.79% on the day but still up 71.20% over the past 30 days. The stock briefly touched a 52-week high of €7.85 on July 16, immediately after the deal became public, before settling back toward the guaranteed cash component. The fixed $6.75 offer price has effectively become a ceiling on the rally, with the current level trading just 19.75% below that peak.
The CVRs represent the swing factor. They are tied to specific clinical and regulatory milestones for Atai Beckley’s two most advanced drug candidates. For VLS-01, a DMT buccal film being developed for depression, shareholders could receive $1.00 per share upon initiation of Phase 3 trials and another $1.00 upon U.S. approval and rescheduling as a controlled substance. Topline data from the ongoing Phase 2b study is expected in the fourth quarter of 2026. For BPL-003, an intranasal 5-MeO-DMT formulation for treatment-resistant depression that is already in Phase 3, the CVRs offer $0.50 per share tied to approval and rescheduling.
Should investors sell immediately? Or is it worth buying Atai Beckley?
The deal has also lifted related names. Compass Pathways, in which Atai Beckley previously held its largest stake, rose 7%. Atai’s ownership in Compass will fall to 4.96% following the transaction’s completion, which is expected in the third quarter of 2026, likely September.
Broader regulatory tailwinds are adding to the sector’s momentum. President Donald Trump has directed the FDA to accelerate the review of substances that have received Breakthrough Therapy designation — a status that both of Atai Beckley’s late-stage depression therapies already hold. That directive likely enhanced Atai’s appeal to Lilly, though it does not change the fact that the stock now trades much closer to the takeover price than to its pre-deal fundamental level.
The company’s operating metrics remain strained. The net profit margin stands at negative 18.32%, cost of goods sold consumes 97.97% of revenue, and operating revenue has declined 38.65% year over year. A cash flow ratio of 0.50 suggests limited new money flowing into the stock, while technical indicators have recently rated the shares as neutral.
Analyst sentiment has shifted as the deal approaches. H.C. Wainwright, which issued a “Strong Buy” rating on Atai Beckley in early June — well before the Lilly offer emerged — has since downgraded to “Neutral.” Jefferies has similarly moved to “Hold.” Both firms cite limited near-term upside beyond the $6.75 cash offer and the inherently speculative nature of the CVR milestones.
The technical picture reinforces the caution. The 14-day relative strength index sits at 74.4, indicating overbought conditions. The stock trades 47.77% above its 50-day moving average of $4.26. Annualized volatility stands at 120.91%, reflecting the heightened uncertainty surrounding the merger timeline and the contingent payouts.
Atai Beckley at a turning point? This analysis reveals what investors need to know now.
For the week ahead, Atai Beckley shares are likely to trade primarily as a merger arbitrage play. Investors will watch for updates on shareholder votes and regulatory filings. The company is also expected to report second-quarter results around August 13, with attention focused less on the financial numbers and more on progress in the Phase 3 ReConnection program for BPL-003 — the program that will determine whether the first CVR tranches are paid out.
The arithmetic is straightforward for current holders. The cash component provides a clearly defined floor, while the CVRs offer a speculative kicker that depends entirely on clinical success and regulatory outcomes. With the stock already trading near the guaranteed payout, the remaining upside is a bet on milestones that may take years to realize — if they happen at all.
Ad
Atai Beckley Stock: New Analysis - 26 July
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
